Gemcitabine Alone or in Combination With Other Chemotherapy Drugs in Treating Patients With Metastatic Cancer of the Pancreas
Part of paid clinical trials in Anniston, Alabama.
- Sponsor
- Alliance for Clinical Trials in Oncology
- Study ID
- NCT00012220
- Phase
- PHASE2
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- cisplatin — DRUG50 mg/sq m IV infusion over 30 min on Days 1 \& 15 of ea cycle
- docetaxel — DRUG40 mg/sq m IV infusion over 60 min on Days 1 \& 8 of ea treatment cycle
- gemcitabine hydrochloride — DRUGGemcitabine only arm: 1500 mg/sq m in 250 mL NS IV infusion over 150 min Days 1, 8, \& 15 of ea cycle * cisplastin arm: 1000 mg/sq m 250 mL NS IV infusion over 30 min Days 1, 8, 15 of ea cycle * docetaxel and + irinotecan arms: 1000 mg/sq m in 250 mL NS IV infusion over 30 min Days 1 \& 8 of ea cycle
- irinotecan hydrochloride — DRUG100 mg/q m in 500 mL D5W or D5NS IV infusion over 90 min Days 1 \& 8 of ea cycle
Study Details
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if gemcitabine is more effective when given alone or in combination with another chemotherapy drug in treating cancer of the pancreas. PURPOSE: Randomized phase II trial to compare the effectiveness of gemcitabine given alone or in combination with other chemotherapy drugs in treating patients who have metastatic cancer of the pancreas.
Key Dates
- Start date
- Jan 31, 2001
- Status verified
- Jul 2016
- Primary completion
- Jun 30, 2004
- Completion
- Apr 30, 2009
Study Design
- Enrollment
- 259 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Active Comparator: GemcitabineStandard treatment
- Experimental: Gemcitabine + cisplastinAddition of cisplastin to gemcitabine
- Experimental: Gemcitabine + docetaxelAddition of docetaxel to gemcitabine
- Experimental: Gemcitabine + IrinotecanAddition of irinotecan to gemcitabine
Primary Outcome Measure
Overall Survival [ Time Frame: 4 years post treatment ]
Locations (75)
Find similar trials in Anniston, AL
By condition
By specialty
By research site
Northeast Alabama Regional Medical Center· Anniston, ALRebecca and John Moores UCSD Cancer Center· La Jolla, CAVeterans Affairs Medical Center - San Diego· San Diego, CAUCSF Comprehensive Cancer Center· San Francisco, CAVeterans Affairs Medical Center - San Francisco· San Francisco, CACCOP - Christiana Care Health Services· Newark, DE
Related Studies
- Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic DisordersRecruiting · Mayo Clinic · Phoenix, Arizona
- PANCREATIC DISEASE COHORT A Registry and Biospecimen Bank to Better Understand Pancreatic DiseaseRecruiting · Columbia University · New York, New York
- Pancreatic Cancer GeneticsRecruiting · Columbia University · New York, New York
- Integrated Cancer Repository for Cancer ResearchRecruiting · University of Nebraska · Greenwood Village, Colorado